NasdaqGS:IBRXBiotechs
ImmunityBio (IBRX) Revenue Ramp To US$38 Million Tests Profitability Optimism
ImmunityBio FY 2025 earnings snapshot
ImmunityBio (IBRX) has reported its FY 2025 results with Q4 revenue of US$38.3 million and a basic EPS loss of US$0.06, alongside net income loss excluding extra items of US$61.9 million. This puts the focus squarely on how quickly the business can scale to cover its cost base. The company has seen quarterly revenue move from US$7.6 million in Q4 2024 to US$16.5 million in Q1 2025, US$26.4 million in Q2 2025, US$32.1 million in Q3 2025 and US$38.3 million...